undefined undefined
NaN.000
NaN.00%
Viking Therapeutics (NASDAQ:VKTX) was a notable decliner among anti-obesity drug developers on Thursday after Swiss pharma giant Roche (OTCQX:RHHBY) said its dual GLP-1/GIP receptor agonist, CT-388, c...
05-17 01:37
Truist Securities analyst Joon Lee reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $120 price target.
05-16 21:58
Viking Therapeutics's (NYSE:VKTX) short percent of float has risen 17.0% since ...
05-15 01:00
Shares of Amgen (NASDAQ:AMGN) rallied 13% in early trading Friday, the day after the biotech giant expressed confidence about its GLP-1 weight-loss drug candidate MariTide during its Q1 earnings call....
05-03 22:28
Whales with a lot of money to spend have taken a noticeably bullish stance on V...
04-30 22:31
Financial giants have made a conspicuous bullish move on Viking Therapeutics. O...
04-27 02:31
Shares of Viking Therapeutics (NASDAQ:VKTX) are down ~4% in after-hours trading Wednesday, even though the company's Q1 2024 financial results beat on the bottom line. Viking did not report any revenu...
04-25 06:25
Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 4 percent decrease over losses of $(0.25) per share from
04-25 04:06
Conference call scheduled for 4:30 p.m. ET today Results From Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Demonstrated Up to 13.1% Placebo-Adjusted Weight Loss (14.7% From B...
04-25 04:05